Janus Kinase V617F mutation in cigarette smokers

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 5-8

  Weinberg, Ido ^a   Borohovitz, Ariel ^a   Krichevsky, Svetlana ^a   Perlman, Riki ^a   Ben Yehuda, Arie ^a   Ben Yehuda, Dina ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRITIN; JANUS KINASE;

ADULT; AGED; ALLELE; ARTICLE; BLOOD CELL COUNT; BLOOD GAS; CASE CONTROL STUDY; CIGARETTE SMOKING; CLINICAL ARTICLE; ERYTHROCYTOSIS; FEMALE; HEMATOCRIT; HOSPITALIZATION; HUMAN; HUMAN CELL; MALE; MUTATION; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; CODON; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION RATE; POLYCYTHEMIA; PREVALENCE; SMOKING;

EID: 84155163125     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22180     Document Type: Article

References (36)

1. Frisancho AR Functional adaptation to high altitude hypoxia. Science 1975; 187: 313-319.
2. Auchincloss JJH, Cook E, Renzetti AD Clinical and physiological aspects of a case of obesity, polycythemia and alveolar hypoventilation. J Clin Invest 1955; 34: 1537-1545.
3. Ernst E, Matrai A, Schmû¶lzl C, Magyarosy I Dose-effect relationship between smoking and blood rheology. Br J Haematol 1987; 65: 485-487.
4. Mast AE, Foster TM, Pinder HL, et al. Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008; 48: 2197-2204.
5. Spiers AS, Levine M Smokers' polycythaemia. Lancet 1983; 1: 120.
6. Tefferi A, Pardanani A Evaluation of "increased" hemoglobin in the JAK2 mutations era: A diagnostic algorithm based on genetic tests. Mayo Clin Proc 2007; 82: 599-604.
7. Rawlings JS, Rosler KM, Harrison DA The JAK/STAT signaling pathway. J Cell Sci 2004; 117: 1281-1283.
8. Ihle JN, Gilliland DG Jak2: Normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007; 17: 8-14.
9. Tefferi A JAK2 mutations in polycythemia vera-molecular mechanisms and clinical applications. N Engl J Med 2007; 356: 444-445.
10. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
11. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
12. James C, Ugo V, Le Couedic J, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
13. Tagariello G, Di Gaetano R, Sartori R, et al. The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels. Blood Transfus 2009; 7: 111-116.
14. Sidon P, El Housni H, Dessars B, Heimann P The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006; 20: 1622.
15. Xu X, Zhang Q, Luo J, et al. JAK2(V617F): Prevalence in a large chinese hospital population. Blood 2007; 109: 339-342.
16. Martinaud C, Brisou P, Mozziconacci M Is the JAK2(V617F) mutation detectable in healthy volunteers? Am J Hematol 2010; 85: 287-288.
17. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006; 20: 350-353.
18. Passamonti F, Rumi E, Pietra D, Lazzarino M, Cazzola M JAK2 (V617F) mutation in healthy individuals. Br J Haematol 2007; 136: 678-679.
19. McClure RF, Hoyer JD, Mai M The JAK2 V617F mutation is absent in patients with erythrocytosis due to high oxygen affinity hemoglobin variants. Hemoglobin 2006; 30: 487-489.
20. Tanabe N, Ohnishi K, Fukui H, Ohno R Effect of smoking on the serum concentration of erythropoietin and granulocyte-colony stimulating factor. Intern Med 1997; 36: 680-684.
21. Van Tiel E, Peeters PHM, Smit HA, et al. Quitting smoking may restore hematological characteristics within five years. Ann Epidemiol 2002; 12: 378-388.
22. Haustein K, Krause J, Haustein H, Rasmussen T, Cort N Effects of cigarette smoking or nicotine replacement on cardiovascular risk factors and parameters of haemorheology. J Intern Med 2002; 252: 130-139.
23. Golde DW, Hocking WG, Koeffler HP, Adamson JW Polycythemia: Mechanisms and management. Ann Intern Med 1981; 95: 71-87.
24. Sagone JAL, Balcerzak SP Smoking as a cause of erythrocytosis. Ann Intern Med. 1975; 82: 512-515.
25. Smith JR, Landaw SA Smokers' polycythemia. N Engl J Med 1978; 298: 6-10.
26. McAloon EJ, Streiff RR, Kitchens CS Erythrocytosis associated with carboxyhemoglobinemia in smokers. South Med J 1980; 73: 137-139.
27. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE Increased cell division as a cause of human cancer. Cancer Res 1990; 50: 7415-7421.
28. Branzei D, Foiani M Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008; 9: 297-308.
29. Fagerstrû¶m KO Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978; 3: 235-241.
30. Pearce MS, Hayes L Self-reported smoking status and exhaled carbon monoxide: Results from two population-based epidemiologic studies in the north of england. Chest 2005; 128: 1233-1238.
31. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676-3682.
32. Hecht SS Cigarette smoking and lung cancer: Chemical mechanisms and approaches to prevention. Lancet Oncol 2002; 3: 461-469.
33. Strobbe L, Lestrade P, Hermans MHA, Fijnheer R Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause. Ann Hematol 2007; 86: 801-803.
34. Tefferi A, Sirhan S, Lasho TL, et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 2005; 131: 166-171.
35. Ben Yehuda A, Globerson A, Krichevsky S, et al. Ageing and the mismatch repair system. Mech Ageing Dev 2000; 121: 173-179.
36. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.